1. Experimental Treatment of SIV-Infected Macaques via Autograft of CCR5-Disrupted Hematopoietic Stem and Progenitor Cells
- Author
-
Hongkui Xiao, Li Qin, Jiaojiao Li, Yang Ou, Dickson Adah, Yao Yongchao, Xiaoping Chen, Shiquan Liu, Songlin Yu, and Siting Zhao
- Subjects
0301 basic medicine ,lcsh:QH426-470 ,Genetic enhancement ,viruses ,CD34 ,medicine.disease_cause ,Article ,03 medical and health sciences ,0302 clinical medicine ,Genetics ,medicine ,Progenitor cell ,lcsh:QH573-671 ,Molecular Biology ,biology ,lcsh:Cytology ,Hematopoietic stem cell ,virus diseases ,Simian immunodeficiency virus ,biology.organism_classification ,Virology ,Transplantation ,Haematopoiesis ,lcsh:Genetics ,030104 developmental biology ,medicine.anatomical_structure ,030220 oncology & carcinogenesis ,Lentivirus ,Molecular Medicine - Abstract
Hematopoietic stem cell (HSC)-based gene therapy targeting CCR5 represents a promising way to cure human immunodeficiency virus type 1 (HIV-1) infection. Yet the preclinical animal model with transplantation of autologous CCR5-ablated HSCs remains to be optimized. In this study, four Chinese rhesus macaques of simian immunodeficiency virus (SIV) chronic infection were given long-term antiretroviral therapy (ART), during which peripheral CD34+ hematopoietic stem and progenitor cells (HSPCs) were purified and infected with CCR5-specific CRISPR/Cas9 lentivirus (three monkeys) or GFP lentivirus (one monkey). After non-myeloablative conditioning, the CCR5-modified or GFP-labeled HSPCs were autotransplanted to four recipients, and ART was withdrawn following engraftment. All of the recipients survived the process of transplantation. The purified CD34+ HSPCs harbored an undetectable level of integrated SIV DNA. The efficiency of CCR5 disruption in HSPCs ranges from 6.5% to 15.6%. Animals experienced a comparable level of hematopoietic reconstuction and displayed a similar physiological homeostasis Despite the low-level editing of CCR5 in vivo (0.3%–1%), the CCR5-disrupted cells in peripheral CD4+ Effector Memory T cell (TEM) subsets were enriched 2- to 3-fold after cessation of ART. Moreover, two of the three treated monkeys displayed a delayed viral rebound and a moderately recovered immune function 6 months after ART withdrawal. This study highlights the importance of improving the CCR5-editing efficacy and augmenting the virus-specific immunity for effective treatment of HIV-1 infection., Graphical Abstract, CRISPR/Cas9-based gene editing holds great promise in HIV-1 treatment. Chen and colleagues autotransplanted the CRISPR-mediated CCR5-disrupted HSPCs to simian immunodeficiency virus (SIV)-infected monkeys. A low-level editing of CCR5 was compensated with a remarkable enrichment of CCR5-disrupted CD4+ TEMs after ART withdrawal and a delayed viral rebound in two out of three treated monkeys.
- Published
- 2020